Other Clinical Trial - Camrelizumab /Apatinib for Recurrent

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT05145218` - A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer	Phase 3
	Completed	`NCT01653912` - Dose-finding Study in Platinum-Resistant Ovarian Cancer	Phase 1/Phase 2

See also

Status

Clinical Trial

Phase

Recruiting

NCT05145218 - A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer

Phase 3

Completed

NCT01653912 - Dose-finding Study in Platinum-Resistant Ovarian Cancer

Phase 1/Phase 2

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT04068974
Study type	Interventional
Source	Peking Union Medical College Hospital
Contact	Pan Lingya
Phone	010-69156204
Email	Panly@pumch.cn
Status	Recruiting
Phase	Phase 2
Start date	October 28, 2019
Completion date	June 30, 2022

Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms